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 Abstract 
 
Progress in the molecular oncology in head and neck cancer (HNSCC) 
depends on high quality appropriate tissue samples for research.  The 
expanding availability of new molecular platforms makes ever increasing 
demands on any available biospecimens.  HNSCC offers several key 
advantages over other tumour sites to the cancer researcher such that, 
through effective tissue collection, clinicians will be of great help the basic 
scientist.  Informed consent and ethical approval are pre-requisites for tissue 
banking and it is vital to develop protocols for collection and storage such that 
the best possible quality of tissue is utilised in future research.  
 Introduction 
 
Advances in understanding the basic science of cancer are dependent upon, 
and to great extent limited by, the availability of high quality appropriate tissue 
samples for research. Increasingly, the introduction of new therapeutic agents 
is also dependent on demonstrated efficacy in human tumour tissue or cell 
cultures.  Recent acceleration in the availability of new technological 
platforms, dubbed “the omics revolution”, also makes great demands on any 
tissue available for research at the DNA, mRNA and expressed protein levels.  
Limitations of quality and quantity of available tissue are common even in 
those institutions where a commitment to collection exists. These may be due 
to restrictions in the scope of patient consent, rarity of the disease concerned, 
methods of storage or inadequate accompanying clinical data.  Often the 
tissue available may prove to be necrotic, be incorrectly diagnosed or simply 
be of inadequate size. Consequently a co-ordinated and multidisciplinary 
approach is essential when designing the process of tissue banking in order 
to maximise the future benefit to research. This review concentrates on some 
of the issues pertinent to head and neck cancer, which actually offers notable 
advantages over many other common cancer sites and thus constitutes an 
attractive model to basic science researchers. We also aim to focus on critical 
issues such ethical approval and consent, as well as practical and logistical 
aspects of tissue collection and storage.  Ultimately our aim is to enhance the 
quality of both the basic and translational research carried out in head and 
neck cancer, hopefully to the benefit of our future patients. 
 Issues specific to head and neck squamous cell 
cancer (HNSCC) 
 
HNSCC offers both theoretical and logistical advantages over other perhaps 
more common tumours.  The majority of malignancies are open to 
examination and incisional biopsy with very limited demands for anaesthesia 
or equipment. Clinically recognisable premalignant lesions are common and 
provide material on which molecular changes that promote malignant 
transformation in such precursor lesions can be studied.  
 
Primary surgery is often indicated for HNSCC, whereas this is less likely to be 
the case for other upper aerodigestive tract carcinomas that share similar 
aetiological and histological features, for example oesophageal and bronchial 
squamous cell carcinoma. This provides the opportunity for collection of good 
quality, previously untreated tumour and control “normal” tissue. The surface 
origin of the tumour means that this can be achieved without disruption or the 
need to “open up” the surgical specimen as is necessary in many other 
tumour types including renal, upper and lower gastrointestinal tract, 
pancreatic and lung, and thus potentially interfere with histopathological gross 
examination.  
 
Approximately 50% of patients treated by surgery have cervical lymph node 
metastasis
1 and many patients undergo concurrent neck dissection. This 
provides an additional opportunity to study the determinants of metastasis by 
molecular comparison of metastasising and non-metastasising primary 
tumours and also tumour deposits from the nodes. Overall survival is quite 
high (e.g. 59% at 5 years
2), allowing for longitudinal follow-up and the 
possibility for identification of molecular markers of prognostic significance as 
well as metachronous disease. Radiotherapy is also frequently indicated 
providing a chance to study potential markers and mechanisms of radio-
resistance.    
 
As well as HNSCC, other less frequent tumours may be of interest. Salivary 
gland neoplasms comprise 6% of head and neck cancers and 0.3% of all 
malignancies in the US. Prospective tissue collection in this setting is 
complicated by the relative rarity, particularly of malignancies, as well as a 
diversity of tumour types. Because of this, it would take many years for a 
single institution to collect a reasonable number of any one type. Additionally, 
pre-operative diagnosis of major gland tumours is limited by reliance on fine 
needle aspiration cytology which often lacks the ability to precisely define the 
tumour type pre-operatively making selection of patients for recruitment into 
tissue collection studies difficult. A further complicating factor is the existence 
of hybrid tumours and malignant transformation of benign pleomorphic 
adenoma in which multiple patterns of carcinomas are possible. In these 
situations, gaining a representative sample of fresh tissue would be 
impossible and distinction between benign and malignant components may 
not be obvious. Finally, disruption of the specimen would always be 
necessary to harvest fresh tumour tissue.  
 What tissue should be collected? 
 
Snap frozen fresh tissue 
 
In terms of many types of molecular research, this is the gold standard and in 
certain situations, the only acceptable tissue on which assays have been 
validated.  
 
We firstly describe a simple model of tissue collection, relying only on the 
surgical team. Upon removal of the tumour from the patient, a 5mm
3 piece of 
tissue is carefully dissected from the centre of the visible tumour and a 
similarly sized piece of normal tissue taken from the wound at the edge of the 
tumour resection. It is imperative not to take normal tissue from the edge of 
the actual resection specimen since this could result in incorrect reporting of a 
close or even involved margin by the pathologist. The samples are transferred 
into cryovials that are pre-labelled with a unique identifying research code. 
One member of the team takes responsibility for updating our research 
database to ensure that patient identifying details are linked to these codes. 
Although this might seem a trivial point, it is vital to label the actual container 
using a permanent marker as problems of sticky labels becoming displaced 
and certain types of marker rubbing off have been encountered. These 
samples are then snap frozen in liquid nitrogen and transferred to a suitable 
freezer, usually –80  C. Temperatures of –80  C induce a reversible change 
in the physical state of the tissue and enzyme inactivation means that nucleic 
acids and proteins are chemically preserved.   
 
The time interval between removal from the patient and method and 
temperature of freezing are each critical to success. One study has shown 
that initial changes in gene and protein expression profiles occur just 5-10 
minutes after colon resection. Fifteen minutes after surgery, 10-15% of all 
detectable genes and proteins differed significantly from baseline and by 30 
minutes, this figure was 20%
3. Others have concluded that it is prudent to 
snap freeze tissue as soon as possible after removal and ideally within 30-60 
minutes
4. Ischaemia related to pre-resection interruption of vascular pedicles 
in order to promote a dry operating field cannot be controlled.  Alternatives to 
liquid nitrogen such as isopentane are available and have been suggested to 
cause less damage. Slow-freezing at -80
oC is not recommended. Storage 
temperatures higher than –80
oC are inadequate for successful preservation 
for extended periods of time
5. 
 
There are limitations in tissue collection in this way. Firstly, there is no way of 
knowing precisely what has been collected and in some circumstances the 
tissue may be entirely necrotic or consist predominantly of granulation tissue 
at the site of previous biopsy. Ideally, a co-registered frozen section stained 
with haematoxylin and eosin (H&E) of the frozen specimen should be 
prepared and examined at the time of resection. This confirms the presence 
of viable tumour, quantifies the percentage of tumour and stroma cells and 
also nature of the stroma such as a dense inflammatory cell infiltrate. 
However this refinement relies on the presence of a histopathologist to be available at all resections which has both logistical and economic implications. 
It is also important to define what constitutes “normal” control tissue. HNSCC 
often arises within field change and the whole of the exposed mucosa, despite 
being clinically and sometimes even histologically normal, may harbour some 
of the genetic and epigenetic changes that are seen in the invasive tumour
6. A 
frozen section of “normal” tissue from the resection margin would confirm the 
absence of tumour and perhaps allow identification of high-grade dysplasia 
but would not be appropriate for detection of mild or moderate dysplasia.   
 
Harvesting of tissue from lymph nodes is more controversial. It is considered 
essential that lymph nodes removed from the patient are subject to 
pathological examination since presence of small clinically and radiologically 
undetectable metastases are seen in around 30% of patients and influences 
prognosis and further management. Even isolated nodes containing 
microscopic extracapsular spread have a drastic impact on survival
7 and may 
influence the decision regarding post-operative radiotherapy, thus it is vital 
that these are identified and reported. It may therefore, be unacceptable to 
submit whole lymph nodes for research and collection of fresh nodal tissue 
should be limited to cases with gross metastatic disease where perhaps 
needle cores of firm, palpable nodes are a good way of acquiring tissue 
without too much disruption to the specimen.  
 
There are few contraindications to tissue collection for research purposes 
other than inability or unwillingness to give consent. In addition, very small 
tumours where removal of the research sample might leave little or none left 
for pathological assessment are clearly ones to avoid. Also when the patient 
is known to have an infectious disease such as HIV or hepatitis B or C, it is 
preferable not to harvest tissue. 
 
 
 
Applications of fresh frozen tissue 
 
Reasonable quality nucleic acids and proteins can be obtained from frozen 
tissue that is suitable for a multitude of molecular analyses including genomic 
assays such as comparative genomic hybridisation, quantification of gene 
expression by measurement of transcribed RNA and also newer technologies 
involving quantification and identification of protein products (proteomics). 
Compared with the more robust nature of DNA, RNA extraction can be 
problematic but is at least possible with fresh tissue. Ding et al.
8 report a 
vastly increased RNA yield when comparing frozen and fixed lung tissue and 
better integrity of 18S and 28S sub-units in the former. Transcripts of mRNA 
molecules of interest can be detected and quantified by modifications of PCR 
reactions. The most widespread use of extracted tumour cell RNA in recent 
years has been in DNA microarray assays in which the expression of 
thousands of genes can be analysed in one single experiment. 
 Formalin fixed paraffin embedded (FFPE) tissue 
 
The major advantage that FFPE tissue offers over fresh frozen tissue is in its 
relative abundance within the archives of pathology departments, even rare 
tumour types will eventually be accumulated.   
 
Fixation of surgically removed tissue has been employed for decades with the 
purpose of preservation of cells and other tissue constituents in a 
morphological condition identical to that seen in life and to do this in a way 
that allows preparation of stained sections
9. Numerous types of fixatives have 
been described but formaldehyde based chemicals have remained the 
chemical of choice for possibly a century. Currently 10% neutral buffered 
formalin (4% formaldehyde) is the fixative of choice in diagnostic pathology. 
Stabilisation of proteins by covalent cross-linking of adjacent amino acids 
renders the proteins insoluble and immobile. Since proteins form the bulk of 
the structural intra and extracellular matrix, both cellular and stromal 
architecture are preserved. In addition, enzymes capable of causing 
autodigestion of the cells and supporting stroma are rendered inactive. 
However, chemical changes occur in nucleic acids and proteins, which may 
limit use of the tissue for molecular analysis, either for the purposes of further 
defining the diagnosis or for molecular research
10;11.  
 
In addition, nucleic sequence modifications are reported which may impact on 
the ability of primers, designed to interact with a specific sequence in a PCR 
amplification reaction, to bind to their target. One mutation artefact per 500 
bases has been estimated
12. Attention to extraction techniques and careful 
primer design for PCR reactions mean that DNA extracted from FFPE tissue 
is however suitable and successful in many molecular techniques aimed at 
detection of gene amplification, deletion (LOH) and mutation.  FFPE tissue 
also seems amenable to methylation assays of tumour suppressor genes 
using pyrosequencing technologies
13.  
 
FFPE tissue is not considered ideal for RNA and some DNA applications. 
RNA is a much more labile molecule than DNA due to high tissue 
concentrations of endogenous lytic enzymes and is substantially degraded by 
formalin fixation and paraffin embedding
14.  Recent reports, however, have 
made some progress in this area. These include comparisons between fresh 
and fixed tissue from the same patients and cell lines subjected to real time 
quantitative reverse transcriptase PCR
15, array CGH
16 and even Affymetrix 
GeneChip analysis
17;18. Time spent fixing in formalin does appear to be 
important particularly in terms of RNA yields and quality and DNA integrity 
with <20 hours seemingly important
16. The reliability of this tissue resource in 
terms of many of these technologies is not fully validated as yet and frozen 
tissue remains the gold standard.  
 
Applications of FFPE tissue  
 
Immunohistochemistry (IHC) 
 Cross-linking of proteins may destroy or significantly modify epitopes of 
interest
11 for which complementary labelled antibodies or immunoprobes 
might be generated. Methods of “unmasking” molecular sequences and 
structures that would be otherwise be obscured by tissue processing are well 
developed
10 and thus IHC has become as important in diagnosis and 
subclassification of many tumours (lymphomas in particular) as the more 
traditional histochemical stains and is applicable to FFPE tissue.  
 
IHC is a valuable research tool to verify protein products where precise 
localisation in morphologically preserved tissue is important. Microscopic 
examination of the stained tissue section permits confirmation that the 
molecule of interest is specifically expressed in tumour cells rather than 
stromal or inflammatory cells at the periphery and also within the expected 
cellular compartment (nuclear versus cytoplasmic). Over-fixation may 
frequently be a problem due to increased epitope modification. There is 
geographic variability of immunohistochemical staining in archival tissue 
sections and this probably represents differences in diffusion of formalin into 
large resection specimens. To ensure optimal and equal fixation, an attractive 
option is to harvest an additional sample of tumour and normal tissue, 5mm
3, 
and place immediately into cassettes pre-coded with a unique research 
number which are then immersed in formalin for a fixed period prior to paraffin 
embedding.   
 
Tissue Microarray (TMA) 
 
TMA technology has taken these applications even further and involves 
carefully selecting areas of interest and taking small (0.5-5mm diameter) 
cores from the FFPE tissue block and inserting them into a specially 
constructed receptor block. Normal, dysplastic, tumour, invasive front and 
metastasis cores can be selected from the same block or patient.  This allows 
for simultaneous immunohistochemical staining or ISH (see below) of 
hundreds of tumour samples, rapid analysis and in-built quality control. 
Studies have verified that examination of such a small amount of tissue is 
representative of the tumour as a whole
19-20. 
 
In-situ hybridisation (ISH) 
 
ISH uses labelled nucleic acid probes to specific DNA or RNA sequences of 
interest. As in immunohistochemistry, precise localisation in architecturally 
preserved tissue is possible but has limited sensitivity. Probes may in certain 
conditions bind to similar sequences that are not a perfect match and so there 
is always a degree of cross-reactivity. A gene affected by a point mutation will 
also hybridise as efficiently as its normal counterpart and so this technique is 
ineffective in detecting such small variations in base sequence
21.  
 
Laser capture microdissection (LCM) 
 
LCM is applicable to both FFPE and fresh frozen tissue. Individual cells or 
groups of cells can be dissected from a stained tissue sections thereby 
ensuring a pure collection of tumour or normal cells for further analysis and overcoming the problem of tissue heterogeneity. An important example is 
when determining loss of heterozygosity of tumour suppressor genes. 
Presence of large numbers of stromal or inflammatory cells will artificially 
equalise the allelic loss and lead to false negative results
14. When examining 
expression of genes by measurement of mRNA levels, results can be 
confounded by expression of the sequence of interest in normal stromal / 
inflammatory cells
14. Reddy et al.
22 have reported methylation of DAP Kinase 
as a normal phenomenon in B lymphocytes which further supports the need to 
remove confounding factors in molecular assays.   
 
New developments in tissue fixatives/preservatives 
 
The conflicting demands of tissue collection for research and preservation of 
the specimen pathological assessment has led to attempts to find an ideal 
fixative that produces adequate histomorphological preservation for diagnosis 
(at least equivalent to that of formaldehyde) and also preserves nucleic acids 
and proteins for molecular analysis. Ethanol fixation offers an alternative to 
formalin in terms of preservation of RNA and also shows comparable 
histology and immunostaining
23. HOPE-fixation (Hepes-Glutamic acid buffer 
mediated Organic solvent Protection Effect) followed by paraffin embedding 
also protects macromolecules including DNA, RNA and proteins whilst 
maintaining histomorphology to allow for accurate histopathological 
assessment and tumour grading. Goldmann et al
24 have successfully applied 
all common molecular techniques on HOPE fixed tissue. An alternative is to 
place the excised tissue specimen into RNAlater.  Florell et al.
25 have shown 
that cytomorphological detail preservation analogous to formalin fixation is 
achieved with the advantage of RNA preservation. Vineck
26  describe a further 
alternative, UMFIX, and concluded that it was possible to preserve 
histomorphology and intact macromolecules.  Since the overriding concern 
following tumour resection must be proper histopathological reporting 
including detailed assessment of prognostic factors, marginal status and 
pathological staging utilising Royal College of Pathologist Minimum Data 
Sets
27, tissue collection for research at present must be regarded as a 
separate event until alternative methods to formalin fixation are fully validated 
by researchers and tested and accepted by reporting pathologists. 
 Surrogate samples (e.g. plasma, saliva, oral rinse, 
oral brushings) 
 
Tumour-derived free DNA has been found in the plasma of some HNSCC 
patients and interest is increasing in the diagnostic and prognostic 
implications of this readily accessible source. The presence of circulating DNA 
demonstrating genetic and epigenetic alterations that correlate with those 
observed in the primary tumour has been associated with advanced tumour 
stage and metastatic disease in HNSCC
28,29. It has been suggested that as 
tumour metastasis results from migration of tumour cells out of the primary 
site, detection of certain proteins or tumour cells in nodes, lymphatics or blood 
may correlate with prognosis. The potential advantages of these minimally 
invasive specimens are apparent; however this places additional demands on 
tissue banking methods. Exactly what surrogate tissue should be collected 
(whole blood, plasma, serum etc.) and at which stage of treatment? Are the 
demands of serum proteomics the same as for circulating DNA? 
 
It is also apparent that the collection of surrogate samples from the same 
body compartment as the tumour may also be of potential clinical value. As an 
example, sputum samples in the field of lung cancer
30 or urine sample in 
bladder cancer
31 have been investigated as methods of screening and 
surveillance.  In HNSCC, it has been shown that DNA methylation in saliva
32 
or oral exfoliated cells
33 may be an early indicator of tumour recurrence. 
Clearly there are many surrogate samples that may hold diagnostic potential 
hold tumour specific aberrations at DNA, RNA or protein level.  The methods 
of collection, storage and processing may prove critical to the success of the 
end application. Whilst detailed description of various methods employed may 
be beyond this paper, it is the author’s practice to collect plasma, white cells 
and pre-operative saliva in HNSCC patients. Co-registration of clinical, pathological and 
molecular data 
 
Tumour boards (in UK the “MDT”) provide an opportunity for identification of 
potential patients to take part in a tissue collection programme and database 
recording of relevant clinical information including medical history, alcohol 
consumption and past and current smoking habits. Patients suffering 
locoregional recurrence, distant metastasis and metachronous second 
primary tumours are also discussed providing an ideal method of recording 
the course of the disease. Given that follow-up will be for length of survival, 
accurate longitudinal data can potentially be acquired for each collected 
sample.  
 
Molecular data is recorded separately using unique identifying codes to 
protect patient confidentiality but a senior member of the research team 
(nominally a clinician) retains the ability to decode the tissue samples and 
relate molecular differences between tumours back to the patient, in particular 
to correlate behavioural differences and response to therapy to research 
findings. Additional histological data regarding tumour invasive front grading 
may be usefully added (e.g. Anneroth score
34), and in a recent report a 
correlation of stromal inflammatory response with increased methylation of a 
panel of tumour suppressor genes was observed in a cohort of OSCC 
patients
35.  
 
  Regulatory aspects of tissue banking: international 
perspectives. 
 
UK Legislation 
 
Until 2001, tissue collection and research thereon was governed by Human 
Tissue Act of 1961 in which there were no requirements for individual patient 
consent. The Retained Organs Commission was set up in 2001 following an 
inquiry into the retention of organs at Alder Hey Children’s Hospital
36 in 
Liverpool and as a result of this it was decided that the Act was out-dated and 
that a paternalistic approach to utilising patient’s tissues without consent was 
no longer appropriate. In 2004, the updated Human Tissue Act (HTA)
37 
created a much more rigid legal framework and the Human Tissue Authority 
was established to supervise compliance.  
 
The overwhelming change in the HTA is that now it is not sufficient for 
patients to opt out of donation of surplus tissue for research, they must now 
give appropriate specific consent for use of their tissue for purposes beyond 
diagnosis. Penalties of up to 3 years imprisonment for breaches of the Act 
exist. A guidance document issued by the Department of Health
37 states that 
consent is not required for use of surplus tissue for research purposes 
provided that ethics committee approval has been granted but with the 
stipulation that the researcher cannot identify the donor tissue and is unlikely 
to be able to do so in the future. In some studies though, follow-up information 
is desirable to link molecular findings to prognosis. Existing tissue that has 
been collected for research purposes prior to implementation of the HTA does 
not require consent.  
 
The requirement to hold a license to store collected tissue is a central aspect 
of the HTA. If collection is undertaken for a specific research project that has 
been given approval by an ethics committee, a tissue licence is not required. 
Consent is an obvious pre-requisite. However, if tissue is being “banked” with 
no specific active or approved project in mind, the HTA stipulates that a 
license is required and the Human Tissue Authority is responsible for granting 
of these. The above caveats are relevant to tissue removed from living 
persons only.  
 
European legislation 
 
Two major international organisations shape the tissue banking and 
transplantation regulations in Europe: the Council of Europe (CoE) and the 
European Union (EU). Several non-governmental organisations also exist 
including the European Association of Tissue Banking (EATB). The CoE’s 
1994 recommendation on human tissue banking states that, in the 
procurement and distribution of human tissues, the ethical principles should 
be respected under all circumstances and makes consent a requirement for 
the removal of tissues and their proposed use. Although this document 
provides important guidance for governments and researchers, it is only a form of political advice and cannot be enforced- the implementation is left to 
the government of individual member states. Article 152 of the Treaty of 
Amsterdam (1997) provides the legal basis of the EU’s directive for setting 
standards of quality on human tissues and cells. These regulations have to be 
transposed into the legislations of the 25 member states within two years of 
their adoption by the EU. 
 
US Perspective 
 
In the United States, there have been organized attempts at local, regional 
and national levels to establish tissue registries for head and neck tumours. 
The most coordinated and notable efforts have occurred with the American 
College of Surgeons Oncology Group (ACOSOG) and the Radiation 
Treatment Oncology Group (RTOG). The ACOSOG was initiated in 1995 
within the American College of Surgeons (ACS) to support cooperative 
activities with the National Cancer Institute Database (NCI).  ACOSOG 
regularly evaluate new clinical trials, accrue patients to active trials and 
monitor established trials.  
 
The tissue bank is a critical feature of the ACOSOG protocols.  The ACOSOG 
Tissue Bank is currently located at Washington University in St Louis and is 
the central site for all tumour specimens and this site also collects 
corresponding demographic data that is being collected. As the number and 
complexity of the ACOSOG trials continues to increase, a major goal will be to 
develop additional methods of cost effective transportation of biospecimens in 
a way that best preserves their molecular integrity. 
 
The Radiation Treatment Oncology Group (RTOG) is a multi-institutional 
collaborative group whose principal objective is to run clinical trials in 
association with the NCI. There are over fifty-two institutions currently enrolled 
with over 40 active protocols at the present time. With regard to head and 
neck disease, the RTOG has established a separate tissue repository under 
the title RTOG 0514 to serve a resource for current and future studies in head 
and neck oncology. The tissue bank is located LDS hospital in Salt Lake City, 
Utah. The RTOG has well-developed and specific criteria for the submission 
of tissue. Firstly all tumour sites must be histologically proven as malignancy 
or premalignant lesions. Typically two 5mm tumour samples from the centre 
of the lesion are submitted. A 5mm tissue sample of grossly “normal” adjacent 
mucosa is also included separately. Sections of metastatic and non-involved 
lymph node are also submitted. These specimens are typically processed in 
the frozen section pathology laboratory and the process is similar for fresh 
and frozen tissue specimens. Optional additional specimens such as 
peripheral blood, saliva, buccal mucosa are also included when appropriate.   Summary 
 
Future translational cancer research relies upon optimised collection of fresh 
tumour and normal tissue as well as surrogates. We have also emphasised 
the importance of archival FFPE tissue for many research applications and 
the scope of these is likely to broaden in the future with new technology.  
Appropriate patient consent and ethical approval are pre-requisites for tissue 
banking although the details will differ between jurisdictions. It is vital to 
develop protocols of collection and storage with the aim of ensuring that only 
high quality tissue is utilised in future research.  
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